The double ring, spool-like structure of RAD52 protects replicating DNA in dividing cells. A study led by the University of ...

A new study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP ...

Inherited mutations in the gene BRCA2 significantly increase the risk of carriers to breast and ovarian cancers.  BRCA2, a crucial player in the body& | Cancer ...

A University of Iowa-led study has revealed the unexpected structure adopted by the DNA repair protein RAD52 as it binds and ...

Imunon is initiating sites for the trial and collaborating with investigators to commence participant enrolment.

A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors.

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...

IMUNON (IMNN) announced that the U.S. Food and Drug Administration is aligned with the protocol for the Phase 3 pivotal trial, called OVATION ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On ...

Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment ...